- Home
- AGIO vs BV Comparison
AGIO vs BV Comparison
Compare AGIO & BV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BV
- Stock Information
- Founded
- AGIO 2007
- BV 1939
- Country
- AGIO United States
- BV United States
- Employees
- AGIO N/A
- BV N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BV Business Services
- Sector
- AGIO Health Care
- BV Consumer Discretionary
- Exchange
- AGIO Nasdaq
- BV Nasdaq
- Market Cap
- AGIO 1.4B
- BV 1.5B
- IPO Year
- AGIO 2013
- BV 2018
- Fundamental
- Price
- AGIO $39.05
- BV $15.53
- Analyst Decision
- AGIO Buy
- BV Buy
- Analyst Count
- AGIO 6
- BV 8
- Target Price
- AGIO $58.60
- BV $17.27
- AVG Volume (30 Days)
- AGIO 602.7K
- BV 950.2K
- Earning Date
- AGIO 07-31-2025
- BV 08-06-2025
- Dividend Yield
- AGIO N/A
- BV N/A
- EPS Growth
- AGIO N/A
- BV N/A
- EPS
- AGIO 11.45
- BV N/A
- Revenue
- AGIO $37,035,000.00
- BV $2,729,300,000.00
- Revenue This Year
- AGIO $22.30
- BV $3.61
- Revenue Next Year
- AGIO $219.19
- BV $2.96
- P/E Ratio
- AGIO $3.45
- BV N/A
- Revenue Growth
- AGIO 25.96
- BV N/A
- 52 Week Low
- AGIO $23.42
- BV $11.81
- 52 Week High
- AGIO $62.58
- BV $18.89
- Technical
- Relative Strength Index (RSI)
- AGIO 70.00
- BV 46.51
- Support Level
- AGIO $34.60
- BV $15.22
- Resistance Level
- AGIO $40.06
- BV $15.73
- Average True Range (ATR)
- AGIO 1.49
- BV 0.47
- MACD
- AGIO 0.43
- BV -0.09
- Stochastic Oscillator
- AGIO 86.59
- BV 47.83
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BV BrightView Holdings Inc.
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.